Active, not recruitingNCT03432520

Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A

Studying Hemophilia

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Spark Therapeutics, Inc.
Principal Investigator: Clinical Trial Director
Spark Therapeutics, Inc.
Intervention: SPK-8011(genetic)
Enrollment: 29 enrolled
Eligibility: 18 years · MALE
Timeline: 2018 – 2032

Study locations (12)

Boston Children's Hospital, Boston, Massachusetts, United States
Mississippi Center for Advanced Medicine, Madison, Mississippi, United States
Truman Medical Centers, Kansas City, Missouri, United States
Oregon Health & Science University, Portland, Oregon, United States
Pennsylvania State University Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, United States
Virginia Commonwealth University, Richmond, Virginia, United States
Royal Prince Alfred Hospital Department of Cell & Molecular Therapies, Sydney, New South Wales, Australia
The Alfred Hospital & Monash Medical Centre, Melbourne, Victoria, Australia
St. Michael's Hospital, Toronto, Ontario, Canada

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03432520 on ClinicalTrials.gov

Other trials for Hemophilia

Additional recruiting or active studies for the same condition.

See all trials for Hemophilia →

← Back to all trials